Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy

Neurology

Volumn 68, Issue 1, 2007, Pages 51-55

  Mercuri, E ^a,b   Bertini, E ^c   Messina, S ^d   Solari, A ^e   D'Amico, A ^c   Angelozzi, C ^a   Battini, R ^f   Berardinelli, A ^g   Boffi, P ^h   Bruno, C ⁱ   Cini, C ^f   Colitto, F ^a   Kinali, M ^b   Minetti, C ⁱ   Mongini, T ^h   Morandi, L ^e   Neri, G ^a   Orcesi, S ^g   Pane, M ^a   Pelliccioni, M ^a,j   Pini, A ^k   Tiziano, F D ^a   Villanova, M ^l   Vita, G ^d   Brahe, C ^a   more..

^a CATHOLIC UNIVERSITY   (Italy)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^d UNIVERSITY OF MESSINA   (Italy)

^e DEPARTMENT OF NEUROSURGERY   (Italy)

^f DEPARTMENT OF DEVELOPMENTAL NEUROSCIENCE   (Italy)

^g UNIVERSITY OF PAVIA   (Italy)

^h UNIVERSITY OF TURIN   (Italy)

ⁱ G GASLINI INSTITUTE   (Italy)

^j UILDM   (Italy)

^k MAGGIORE HOSPITAL   (Italy)

^l Nigrisoli Hospital   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARYLBUTYRIC ACID DERIVATIVE; PLACEBO;

ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG WITHDRAWAL; FEMALE; FORCED EXPIRATORY VOLUME; HALLUCINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MOTOR PERFORMANCE; MULTICENTER STUDY; MUSCLE; NAUSEA; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SPINAL MUSCULAR ATROPHY; TREATMENT DURATION;

CHILD; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MUSCULAR ATROPHY, SPINAL; PHENYLBUTYRATES; RETROSPECTIVE STUDIES;

EID: 33846114574     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000249142.82285.d6     Document Type: Article

References (18)

1. Lefebvre S, Burglen L, Reboullet S, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 1995;80:155-165.
2. Mailman MD, Heinz JW, Papp AC, et al. Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2. Genet Med 2002;4:20-26.
3. Brichta L, Hofmann Y, Hahnen E, et al. Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Hum Mol Genet 2003;12:2481-2489.
4. Sumner CJ, Huynh TN, Markowitz JA, et al. Valproic acid increases SMN levels in spinal muscular atrophy patient cells. Ann Neurol 2003;54:647-654.
5. Andreassi C, Angelozzi C, Tiziano FD, et al. Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy. Eur J Hum Genet 2004;12:59-65.
6. Brahe C, Vitali T, Tiziano FD, et al. Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients. Eur J Hum Genet 2005;13:256-259.
7. Mercuri E, Bertini E, Messina S, et al. Pilot trial of phenylbutyrate in spinal muscular atrophy. Neuromuscul Disord 2004;14:130-135.
8. Munsat TL, Davies KS. International SMA consortium meeting (26-28 June 92, Bonn, Germany). Neuromuscul Disord 1992;2:423-428.
9. Atweh GF, Sutton M, Nassif I, et al. Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease. Blood 1999;93:1790-1797.
10. Main M, Kairon H, Mercuri E, Muntoni F. The Hammersmith functional motor scale for children with spinal muscular atrophy: a scale to test ability and monitor progress in children with limited ambulation. Eur J Paediatr Neurol 2003;7:155-159.
11. Mercuri E, Messina S, Battini R, et al. Reliability of the Hammersmith functional motor scale for spinal muscular atrophy in a multicentric study. Neuromuscul Disord 2006;16:93-98.
12. Merlini L, Mazzone ES, Solari A, Morandi L. Reliability of hand-held dynamometry in spinal muscular atrophy. Muscle Nerve 2002;26:64-70.
13. Merlini L, Solari A, Vita G, et al. Role of gabapentin in spinal muscular atrophy: results of a multicenter, randomized Italian study. J Child Neurol 2003;18:537-541.
14. Vickers AJ, Altman DG. Statistics notes: analysing controlled trials with baseline and follow up measurements. BMJ 2001;323:1123-1124.
15. Zerres K, Rudnik-Schonenborn S. Natural history in proximal spinal muscular atrophy. Arch Neurol 1995;52:518-523.
16. Russman BS, Buncher CR, White M, Smaha FJ, Iannaconne ST. Function changes in spinal muscular atrophy II and III. The DCN/SMA groups. Neurology 1996;47:973-976.
17. Kleppe S, Mian A, Lee B. Urea cycle disorders. Curr Treat Options Neurol 2003;5:309-319.
18. Butchbach MER, Le TT, Burghes AHM. Protective effects of butyrate analogues and prodrugs on a mouse model for spinal muscular atrophy. Viewer/Itinerary Planner 2004. Washington, DC: Society for Neuroscience. Abstract.